Literature DB >> 2917591

Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.

T Tateishi1, H Nakashima, T Shitou, Y Kumagai, K Ohashi, S Hosoda, A Ebihara.   

Abstract

The pharmacokinetic interaction between diltiazem and three beta-adrenoceptor blockers propranolol, metoprolol and atenolol was investigated in healthy volunteers given diltiazem 30 mg or placebo t.d.s. for 3 days, followed by a single dose of propranolol 20 mg, metoprolol 40 mg or atenolol 50 mg. The AUCs of propranolol and metoprolol were significantly increased after diltiazem and it significantly prolonged the elimination half-life of metoprolol. In contrast, it did not significantly affect the pharmacokinetics of atenolol. Propranolol significantly decreased the resting pulse rate after diltiazem pretreatment as compared to placebo. The results indicate that diltiazem impaired the clearance of propranolol and metoprolol, which are principally metabolized by an oxidative pathway, and that the kinetic interaction between diltiazem and propranolol may partly be related to the significant reduction in the pulse rate produced by the latter.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917591     DOI: 10.1007/BF00561026

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

Review 1.  Bioavailability of drugs (first of two parts).

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1974-08-01       Impact factor: 91.245

2.  An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents.

Authors:  P B Woods; M L Robinson
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

Review 3.  The clinical importance of cardioselectivity and lipophilicity in beta blockers.

Authors:  J M Cruickshank
Journal:  Am Heart J       Date:  1980-08       Impact factor: 4.749

4.  The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study.

Authors:  J Hung; I H Lamb; S J Connolly; K R Jutzy; M L Goris; J S Schroeder
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

5.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.

Authors:  G Carrum; J M Egan; D R Abernethy
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

Review 7.  Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy.

Authors:  R M Brouwer; F Follath; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris.

Authors:  N Toyosaki; T Toyo-oka; T Natsume; T Katsuki; T Tateishi; T Yaginuma; S Hosoda
Journal:  Circulation       Date:  1988-06       Impact factor: 29.690

9.  Superiority of combined diltiazem and propranolol therapy for angina pectoris.

Authors:  W E Strauss; A F Parisi
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

Review 10.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

View more
  11 in total

1.  Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.

Authors:  I Vercruysse; D F Schoors; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 3.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

4.  Evaluation of clinical bradycardiac effect and respiratory adverse effect of β-blocking agents in coronary computed tomography angiography based on theoretical analysis.

Authors:  Kaori Fujito; Risa Takayanagi; Koji Kimura; Haruko Yokoyama; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-16       Impact factor: 2.441

Review 5.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

Authors:  D F Schoors; I Vercruysse; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

7.  The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Authors:  H Sakai; S Kobayashi; K Hamada; S Iida; H Akita; E Tanaka; E Uchida; H Yasuhara
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 8.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

9.  Toxicity of beta-blockers in a rat whole embryo culture: concentration-response relationships and tissue concentrations.

Authors:  S Klug; R Thiel; R Schwabe; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

Review 10.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.